Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29843637 | 1.00 | POLB (0.57) | POLBNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL31588535 | 1.00 | POLB (0.57) | POLBNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL28153180 | 0.98 | POLB (0.55) | POLBNPC1RAB9AALDH1A1SMN1; SMN2 | |
| Fluoride SCHEMBL28218511 | 0.98 | POLB (0.55) | POLBNPC1RAB9AALDH1A1SMN1; SMN2 | |
| Quinoline SCHEMBL28269682 | 0.95 | ALDH1A1 (0.59) | POLBNPC1RAB9AALDH1A1SMN1; SMN2 | |
| Isoquinoline SCHEMBL28125940 | 0.86 | CYP11B2 (0.47) | POLBNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL3843536 | 0.85 | ALDH1A1 (0.53) | POLBNPC1RAB9AALDH1A1CASP1 | |
| Quinoline SCHEMBL28240764 | 0.84 | ALDH1A1 (0.59) | POLBNPC1RAB9AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL28325576 | 0.83 | ALDH1A1 (0.52) | POLBNPC1RAB9AALDH1A1CASP1 | |
| SCHEMBL27793193 | 0.83 | ALDH1A1 (0.52) | POLBNPC1RAB9AALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058452-B1 | HYDROPYRAZINO[1,2-B]ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2025-07-09 | — | — | EP | claimed |
| CN-118126272-A | Preparation and application of novel transfer hydrogenation catalyst | 中国人民武装警察部队后勤学院 | 2024-06-04 | — | — | CN | claimed |
| EP-3953356-B1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | claimed |
| EP-3856737-B1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-05-17 | — | — | EP | claimed |
| EP-3847170-B1 | NOVEL CYCLIC AMIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2022-06-22 | — | — | EP | claimed |
| US-20220098160-A1 | NOVEL CDK 8/19 INHIBITORS | BIOCAD (RU) | 2022-03-31 | — | — | US | claimed |
| CN-111668536-B | Preparation method of metal aluminum-cyano organic matter secondary battery | 北京科技大学 | 2021-03-23 | — | — | CN | claimed |
| CN-111668536-A | Preparation method of metal aluminum-cyano organic matter secondary battery | 北京科技大学 | 2020-09-15 | — | — | CN | claimed |
| CN-110229102-A | 2- is alkylated quinoline, derivative and its synthetic method | 湘潭大学 | 2019-09-13 | — | — | CN | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| CN-109071462-A | Quinazoline derivative or salt thereof and pharmaceutical composition containing the same | 柳韩洋行 | 2018-12-21 | — | — | CN | claimed |
| CN-105025899-B | Having a2AHeterobicyclically substituted- [1,2,4 ] antagonists]Triazolo [1,5-c]Quinazoline-5-amine compounds | 默沙东公司 | 2017-08-18 | — | — | CN | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| CN-103930418-A | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS INC | 2014-07-16 | — | — | CN | claimed |
| CN-103857675-A | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS INC | 2014-06-11 | — | — | CN | claimed |
| CN-103328452-A | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS INC | 2013-09-25 | — | — | CN | claimed |
| CN-102917590-A | Trycyclic compounds and pbk inhibitors containing the same | ONCOTHERAPY SCIENCE INC | 2013-02-06 | — | — | CN | claimed |
| WO-2008048967-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2008-04-24 | — | — | WO | claimed |
| CN-1237963-A | Quinoline derivatives inhibiting the action of growth factors such as VEGF | ZENECA LTD (GB) | 1999-12-08 | — | — | CN | claimed |
| EP-0675111-A2 | Process for the preparation of 6-hydroxymethyl-quinolines | BASF AKTIENGESELLSCHAFT (DE) | 1995-10-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098160-A1 | NOVEL CDK 8/19 INHIBITORS | CDK8, CDK9, CDK18 | POLB 139/4885NPC1 3811/4885RAB9A 1088/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | POLB 1829/4885NPC1 917/4885RAB9A 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.